GT BIOPHARMA, INC.: 10-Q filed 2015-01-08

Name: GT BIOPHARMA, INC.: 10-Q filed 2015-01-08
Creator: GT BIOPHARMA, INC.

What GT BIOPHARMA, INC. reported in its quarterly report filed 2015-01-08 (fiscal Q2 2014): 33 published measures, 96 facts as tagged in accession 0001513160-15-000010.

This filing

Form: 10-Q (quarterly report)
Filed: 2015-01-08
Fiscal period: fiscal Q2 2014
Accession: 0001513160-15-000010 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All GT BIOPHARMA, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2014-06-30	52,000	USD
At 2013-12-31	147,000	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2014-06-30	7,017,000	USD
At 2013-12-31	6,481,000	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2014-06-30	-6,965,000	USD
At 2013-12-31	-6,334,000	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2014-06-30	1,000	USD
At 2013-12-31	43,000	USD
At 2013-06-30	11,000	USD
At 2012-12-31	123,000	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	-262,000	USD	91
2014-01-01 to 2014-06-30	-633,000	USD	181
2013-04-01 to 2013-06-30	-306,000	USD	91
2013-01-01 to 2013-06-30	162,000	USD	181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2014-01-01 to 2014-06-30	-133,000	USD	181
2013-01-01 to 2013-06-30	-118,000	USD	181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2014-01-01 to 2014-06-30	89,000	USD	181
2013-01-01 to 2013-06-30	1,000	USD	181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2014-06-30	-90,100,000	USD
At 2013-12-31	-89,467,000	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	573,051,524	shares	91
2014-01-01 to 2014-06-30	573,051,524	shares	181
2013-04-01 to 2013-06-30	573,051,524	shares	91
2013-01-01 to 2013-06-30	560,220,983	shares	181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	573,051,524	shares	91
2014-01-01 to 2014-06-30	573,051,524	shares	181
2013-04-01 to 2013-06-30	573,051,524	shares	91
2013-01-01 to 2013-06-30	616,508,334	shares	181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Unit	Days
2014-04-01 to 2014-06-30	USD/shares	91
2014-01-01 to 2014-06-30	USD/shares	181
2013-04-01 to 2013-06-30	USD/shares	91
2013-01-01 to 2013-06-30	USD/shares	181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Unit	Days
2014-04-01 to 2014-06-30	USD/shares	91
2014-01-01 to 2014-06-30	USD/shares	181
2013-04-01 to 2013-06-30	USD/shares	91
2013-01-01 to 2013-06-30	USD/shares	181

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Unit	Days
2014-04-01 to 2014-06-30	USD	91
2014-01-01 to 2014-06-30	USD	181
2013-04-01 to 2013-06-30	USD	91
2013-01-01 to 2013-06-30	USD	181

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2014-01-01 to 2014-06-30	0	USD	181
2013-01-01 to 2013-06-30	175,000	USD	181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	-104,000	USD	91
2014-01-01 to 2014-06-30	-205,000	USD	181
2013-04-01 to 2013-06-30	-74,000	USD	91
2013-01-01 to 2013-06-30	-421,000	USD	181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2014-06-30	32,000	USD
At 2013-12-31	125,000	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	168,000	USD	91
2014-01-01 to 2014-06-30	365,000	USD	181
2013-04-01 to 2013-06-30	256,000	USD	91
2013-01-01 to 2013-06-30	787,000	USD	181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2014-06-30	6,861,000	USD
At 2013-12-31	6,384,000	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2014-06-30	925,000	USD
At 2013-12-31	940,000	USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

Period	Value	Unit	Days
At 2014-06-30	20,000	USD
At 2013-12-31	22,000	USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

Period	Value	Unit	Days
At 2014-06-30	5,000	USD
At 2013-12-31	40,000	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	112,000	USD	91
2014-01-01 to 2014-06-30	213,000	USD	181
2013-04-01 to 2013-06-30	118,000	USD	91
2013-01-01 to 2013-06-30	484,000	USD	181

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

Period	Value	Unit	Days
At 2014-06-30	26,000	USD
At 2013-12-31	42,000	USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	8,000	USD	91
2014-01-01 to 2014-06-30	8,000	USD	181
2013-04-01 to 2013-06-30	44,000	USD	91
2013-01-01 to 2013-06-30	63,000	USD	181

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	112,000	USD	91
2014-01-01 to 2014-06-30	213,000	USD	181
2013-04-01 to 2013-06-30	118,000	USD	91
2013-01-01 to 2013-06-30	484,000	USD	181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Unit	Days
2014-04-01 to 2014-06-30	USD	91
2014-01-01 to 2014-06-30	USD	181
2013-04-01 to 2013-06-30	USD	91
2013-01-01 to 2013-06-30	USD	181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2014-06-30	573,051,524	shares
At 2013-12-31	573,051,524	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2014-06-30	82,709,000	USD
At 2013-12-31	82,709,000	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2014-06-30	1,251,000	USD
At 2013-12-31	1,225,000	USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	-261,000	USD	91
2014-01-01 to 2014-06-30	-631,000	USD	181
2013-04-01 to 2013-06-30	-315,000	USD	91
2013-01-01 to 2013-06-30	167,000	USD	181

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

Period	Value	Unit	Days
2014-01-01 to 2014-06-30	2,000	USD	181
2013-01-01 to 2013-06-30	1,000	USD	181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	-157,000	USD	91
2014-01-01 to 2014-06-30	-426,000	USD	181
2013-04-01 to 2013-06-30	-241,000	USD	91
2013-01-01 to 2013-06-30	588,000	USD	181

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

Period	Value	Unit	Days
2014-01-01 to 2014-06-30	35,000	USD	181
2013-01-01 to 2013-06-30	0	USD	181

Inspect the source

Entity: GT BIOPHARMA, INC. / CIK 0000109657
Captured: 2026-09-19T14:55:07.505Z
SEC response SHA-256: 0714d67deac3d58f2a709d6724403717be9f1cb5b62a0b01bb00eb4ad237a7b1

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000109657.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))